

CURRICULUM VITAE

Name: Prof. Dr. med. Bernhard Hellmich
Born: September 14th 1968 in Unna, Germany
Address: Kreiskliniken Esslingen
Klinik Kirchheim, Klinik für Innere Medizin,
Eugenstraße 3
73230 Kirchheim unter Teck
Germany

Medical Education:

1988-1994 Ruhr-Universität Bochum, Germany, School of Medicine
05/94-09/94 University of California Los Angeles, UCLA School of Medicine

Professional Activities:

1995 Doctoral Thesis (Dr. med. degree): "Phagocytosis of PMN in septic shock. Stimulation with ω -3 fatty acids and arginine in vitro" (Ruhr-Universität Bochum, Bochum, Germany)
1995-1996 Internship: Department of Medicine, Klinikum Bergmannsheil, Ruhr-Universität Bochum, Germany
04.07.1996 Approbation
1996-1998 Residency in Rheumatology: Department of Rheumatology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany
1998-2001.1 Residency in Internal Medicine, Rheumatology and Endocrinology: Dept of Medicine, Klinikum Bergmannsheil, Ruhr-Universität Bochum, Germany
06/2001 Board Certification in Internal Medicine
2002-09/07 Vice Chairman, Department of Rheumatology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck/Rheumaklinik Bad Bramstedt
03/2003 Habilitation (Priv-Doz. degree) & Venia legendi in Internal Medicine. Thesis: "The role of hematopoietic growth factors and anticytokine antibodies for the pathogenesis and treatment of inflammatory rheumatic diseases" (Med. Fakultät der Ruhr-Universität, Bochum, Germany)
2004 Board Certification in Rheumatology
10/07 ong. Chairman, Department of Medicine & Rheumatology, Kreiskliniken Esslingen, Plochingen (2007-2013) and Kirchheim (since 2013)
12/07 ong. Medical Director, Kreiskliniken Esslingen
10/09 Professor of Medicine, Universität Tübingen, Germany

Clinical Trial experience:

1996-1998 Phase III therapeutic studies in ANCA-associated vasculitis (EUVAS studies :CYCAZAREM, NORAM)
2001-2004 LEM-study (MTX versus LEF for WG), Phase III
2002-2003 Adalimumab in RA, Phase IIIb*
2002-2003 Anakinra in RA, Phase IV*
2004-2005 RAPIDS-2 (bosentan for digital ulcers in systemic sclerosis), Phase II / III*
2003-2004 Phase II multicenter study: 15-DSG for refractory Wegener's granulomatosis (*+ principal investigator for Germany)
2003-2005 Rituximab for refractory WG, phase II*
2004-2006 Mepolizumab for Hypereosinophilic syndrome, Phase III*
2005-2007 Mepolizumab for hypereosinophilic syndrome for HES, Phase III*

2005-2007	Tocilizumab for treatment of RA, Phase III*
2005-2007	Infliximab for Lupus nephritis (Phase III)*
2005-2007	Investigational agent for RA (Phase II) (principal investigator for Germany)*
2007-2010	Mepolizumab for Churg-Strauss Syndrome (Phase II) (principal investigator)*
2008-2009	Tocilizumab for treatment of RA (TAMARA) (Phase IV)*
2009-ong.	Rituximab for treatment of RA (Phase IV)*
2009-2010	Tocilizumab for treatment of RA (Phase IV)*
2011-2015	Epratuzumab for treatment of SLE (Phase III) PI for Germany*
2013-ong.	Belimumab for treatment of AAV (Phase III) *
2013-ong.	Mepolizumab in EGPA/Churg Strauss Syndrome (Phase III)
2013-ong	Tocilizumab for giant cell arteriitis (Phase III)*
2015-ong	anti-IL-18 for adult-onset Still disease (Phase II)*
2016-ong	anti-IFN γ for treatment of SLE (Phase III)
2016-ong	exp. agent for systemic sclerosis (Phase III)
2016-ong	exp. agent for giant cell arteriitis (Phase III)

*PI at study site

Other qualifications:

- National Coordinator of the European Vasculitis Study Group (EUVAS)
- Chairman of the EULAR/EUVAS committee for development of recommendations for conduction of clinical trials in vasculitis (see publication: Hellmich B et al.: EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis. *Ann Rheum Dis* 2007; 66:605-17).
- Member EULAR/EUVAS-Guidelines-Committee for the Management of systemic vasculitides (*Ann Rheum Dis.* 2009 Mar;68(3):310-7; *Ann Rheum Dis.* 2009 Mar;68(3):318-23)
- Member of the committees for academic medicine and education of the German Rheumatology Society (DGrh)